Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Colombo
Red Hat Certified System Administrator (RHCSA) - RHEL 10
Sanjeewani95
Updated:
Friday at 7:43 PM
NURSING , CAREGIVER , HOTEL & BEAUTY COURSES
IVA Para Medical Campus
Updated:
Thursday at 9:24 AM
Handmade Character Soft Toys Peppa Pig Family
anil1961
Updated:
Wednesday at 9:58 PM
Ad icon
Video Content Creator
pramukag
Updated:
Jun 28, 2026
Ad icon
QA Engineer Intern
pramukag
Updated:
Jun 28, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
Maglev Powered Titanium Heart Transplant.
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 29996389" data-attributes="member: 562115"><p>The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR's TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart.</p><p></p><p>The first-in-human clinical study aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended. Following this first implantation completed at Baylor St. Luke's Medical Center in the Texas Medical Center, four additional patients are to be enrolled in the study.</p><p></p><p>The pumping motion of the BiVACOR’s Total Artificial Heart (TAH) is governed by a maglev driven rotor, which spins to circulate blood around the body while suspended contactlessly inside the titanium housing of the compact implant. Once installed, the valveless heart is theoretically capable of supporting an exercising adult male, and can be manipulated to pump faster or slower using a smart external controller. It is also hoped that its frictionless design will remove the risk of mechanical wear, and ultimately, failure.</p><p></p><p>On July 9, surgeons at the Texas Medical Center successfully implanted the first human patient with the maglev-powered heart, as part of an FDA approved trial to test the safety and feasibility of the artificial organ. As it stands, BiVACOR’s heart is not being developed as a permanent replacement, but rather as a bridging implant to keep patients alive while they wait for a donor heart to become available.</p><p></p><p>Thankfully, the BiVACOR TAH was able to keep the patient alive for a full eight days, after which surgeons were able to remove the artificial organ in order to replace it with a donor heart on July 17. The patient is now recovering well, according to a recent update from the Texas Heart Institute.</p></blockquote><p></p>
[QUOTE="imhotep, post: 29996389, member: 562115"] The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR's TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart. The first-in-human clinical study aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended. Following this first implantation completed at Baylor St. Luke's Medical Center in the Texas Medical Center, four additional patients are to be enrolled in the study. The pumping motion of the BiVACOR’s Total Artificial Heart (TAH) is governed by a maglev driven rotor, which spins to circulate blood around the body while suspended contactlessly inside the titanium housing of the compact implant. Once installed, the valveless heart is theoretically capable of supporting an exercising adult male, and can be manipulated to pump faster or slower using a smart external controller. It is also hoped that its frictionless design will remove the risk of mechanical wear, and ultimately, failure. On July 9, surgeons at the Texas Medical Center successfully implanted the first human patient with the maglev-powered heart, as part of an FDA approved trial to test the safety and feasibility of the artificial organ. As it stands, BiVACOR’s heart is not being developed as a permanent replacement, but rather as a bridging implant to keep patients alive while they wait for a donor heart to become available. Thankfully, the BiVACOR TAH was able to keep the patient alive for a full eight days, after which surgeons were able to remove the artificial organ in order to replace it with a donor heart on July 17. The patient is now recovering well, according to a recent update from the Texas Heart Institute. [/QUOTE]
Insert quotes…
Verification
Dawasata paya keeyak thibeda?
Post reply
Top
Bottom